Justin Walsh
Stock Analyst at Jones Trading
(1.89)
# 2,838
Out of 4,817 analysts
35
Total ratings
37.5%
Success rate
-9.63%
Average return
Main Sectors:
Stocks Rated by Justin Walsh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MNPR Monopar Therapeutics | Downgrades: Hold | n/a | $40.49 | - | 1 | Apr 2, 2025 | |
| BLRX BioLineRx | Downgrades: Hold | n/a | $2.92 | - | 2 | Apr 2, 2025 | |
| LNTH Lantheus Holdings | Maintains: Buy | $127 → $122 | $100.62 | +21.25% | 8 | Mar 21, 2025 | |
| SER Serina Therapeutics | Initiates: Buy | $11 | $5.27 | +108.73% | 1 | Mar 11, 2025 | |
| ANRO Alto Neuroscience | Initiates: Buy | $18 | $2.32 | +677.54% | 1 | Dec 16, 2024 | |
| RAPP Rapport Therapeutics | Initiates: Buy | $42 | $10.37 | +305.01% | 1 | Oct 18, 2024 | |
| THTX Theratechnologies | Downgrades: Hold | n/a | $2.57 | - | 2 | Oct 11, 2024 | |
| YMAB Y-mAbs Therapeutics | Initiates: Buy | $23 | $4.81 | +378.17% | 1 | Jul 11, 2024 | |
| CATX Perspective Therapeutics | Maintains: Buy | $15 → $22 | $1.94 | +1,036.95% | 2 | May 16, 2024 | |
| TLSI TriSalus Life Sciences | Initiates: Buy | $16 | $5.63 | +184.19% | 1 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $2.23 | +796.86% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $4 | $1.09 | +266.97% | 4 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $1.39 | +1,338.85% | 1 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $0.69 | +2,513.62% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $440 | $3.08 | +14,185.71% | 1 | Feb 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $0.65 | +11,438.46% | 1 | Oct 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $20 | $23.26 | -14.02% | 1 | May 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $440 → $200 | $1.30 | +15,284.62% | 2 | Apr 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.79 | +460.22% | 1 | Jan 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $800 | $9.09 | +8,700.88% | 1 | Sep 2, 2021 |
Monopar Therapeutics
Apr 2, 2025
Downgrades: Hold
Price Target: n/a
Current: $40.49
Upside: -
BioLineRx
Apr 2, 2025
Downgrades: Hold
Price Target: n/a
Current: $2.92
Upside: -
Lantheus Holdings
Mar 21, 2025
Maintains: Buy
Price Target: $127 → $122
Current: $100.62
Upside: +21.25%
Serina Therapeutics
Mar 11, 2025
Initiates: Buy
Price Target: $11
Current: $5.27
Upside: +108.73%
Alto Neuroscience
Dec 16, 2024
Initiates: Buy
Price Target: $18
Current: $2.32
Upside: +677.54%
Rapport Therapeutics
Oct 18, 2024
Initiates: Buy
Price Target: $42
Current: $10.37
Upside: +305.01%
Theratechnologies
Oct 11, 2024
Downgrades: Hold
Price Target: n/a
Current: $2.57
Upside: -
Y-mAbs Therapeutics
Jul 11, 2024
Initiates: Buy
Price Target: $23
Current: $4.81
Upside: +378.17%
Perspective Therapeutics
May 16, 2024
Maintains: Buy
Price Target: $15 → $22
Current: $1.94
Upside: +1,036.95%
TriSalus Life Sciences
May 10, 2024
Initiates: Buy
Price Target: $16
Current: $5.63
Upside: +184.19%
Apr 17, 2024
Initiates: Buy
Price Target: $20
Current: $2.23
Upside: +796.86%
Sep 7, 2023
Reinstates: Buy
Price Target: $4
Current: $1.09
Upside: +266.97%
Sep 6, 2023
Initiates: Buy
Price Target: $20
Current: $1.39
Upside: +1,338.85%
May 16, 2023
Initiates: Buy
Price Target: $18
Current: $0.69
Upside: +2,513.62%
Feb 10, 2023
Initiates: Buy
Price Target: $440
Current: $3.08
Upside: +14,185.71%
Oct 7, 2022
Initiates: Buy
Price Target: $75
Current: $0.65
Upside: +11,438.46%
May 20, 2022
Maintains: Buy
Price Target: $17 → $20
Current: $23.26
Upside: -14.02%
Apr 5, 2022
Maintains: Buy
Price Target: $440 → $200
Current: $1.30
Upside: +15,284.62%
Jan 19, 2022
Initiates: Buy
Price Target: $10
Current: $1.79
Upside: +460.22%
Sep 2, 2021
Initiates: Buy
Price Target: $800
Current: $9.09
Upside: +8,700.88%